Evidence map›Paper›PMID 38476817›Full record

ArticleFrontiers in psychiatry2023

Association of

Masanobu Kogure, Nobuhisa Kanahara, Atsuhiro Miyazawa, Yuki Shiko, Ikuo Otsuka, Koichi Matsuyama, Masayuki Takase, Makoto Kimura, Hiroshi Kimura, Kiyomitsu Ota and 11 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 1 country.

Masanobu KogureDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Nobuhisa KanaharaDivision of Medical Treatment and Rehabilitation, Center for Forensic Mental Health, Chiba University, Chiba, Japan.
Atsuhiro MiyazawaDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Yuki ShikoBiostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Ikuo OtsukaDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Koichi MatsuyamaDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Masayuki TakaseShoushin-kai Mobara Mental Hospital, Mobara, Japan.
Makoto KimuraChiba Psychiatric Medical Center, Chiba, Japan.
Hiroshi KimuraDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Kiyomitsu OtaDoujin-kai Kisarazu Hospital, Kisarazu, Japan.
Keita IdemotoDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Masaki TamuraDoujin-kai Kisarazu Hospital, Kisarazu, Japan.
Yasunori OdaDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Taisuke YoshidaDoujin-kai Kisarazu Hospital, Kisarazu, Japan.
Satoshi OkazakiDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Fumiaki YamasakiDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Yusuke NakataDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Yoshinori WatanabeHimorogi Psychiatric Institute, Tokyo, Japan.
Tomihisa NiitsuDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Akitoyo HishimotoDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Masaomi IyoDepartment of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.
Chiba University · JPKisarazu Hospital · JPKobe University · JPCenter for Forensic Mental Health, Chiba University · JPChiba University Hospital · JPKameda Medical Center · JPTokyo Institute of Psychiatry · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Most genetic analyses that have attempted to identify a locus or loci that can distinguish patients with treatment-resistant schizophrenia (TRS) from those who respond to treatment (non-TRS) have failed. However, evidence from multiple studies suggests that patients with schizophrenia who respond well to antipsychotic medication have a higher dopamine (DA) state in brain synaptic clefts whereas patients with TRS do not show enhanced DA synthesis/release pathways. Patients and methods: To examine the contribution (if any) of genetics to TRS, we conducted a genetic association analysis of DA-related genes in schizophrenia patients (TRS, Results: The distributions of the genotypes of rs3756450 and the 40-bp variable number tandem repeat on Conclusion: The overall results suggest that (

Indexed as

antipsychoticdopaminepsychosissingle nucleotide polymorphismvariable number of tandem repeats

Identifiers

PMID38476817
PMCPMC10929739
OpenAlexW4392200367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.